


ATTY. DOCKET:UCIVN-035A  
Serial No. 10/810,497

This listing of claims will replace all prior versions, listing, of all claims in the application:

What is claimed is:

1. (Withdrawn) A method for inducing CD81 dependent antiproliferation in a human or veterinary patient, said method comprising the step of:

(A) administering to the patient a therapeutically effective amount of an amantadine analogue having the formula:



wherein,

X is Boron or Carbon;


A is NH and NHR<sub>1</sub>, where R<sub>1</sub> is H, alkyl or imino-alkyl amino;

Z is a acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 10 carbon atoms, C=O, SO<sub>2</sub>, or absent; and R is an acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms and -CH-R<sub>2</sub>R<sub>3</sub> -CHR<sub>2</sub>R<sub>3</sub>, wherein R<sub>2</sub> is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, (CH<sub>2</sub>)<sub>n</sub>-Q, where n is 1-4 and Q is BSH, -OH, -NH<sub>2</sub>, -NH-CO-NH<sub>2</sub>, -NH-C=(NR<sub>4</sub>) NHR<sub>5</sub>, -COOH and its alkyl esters, and -CONH<sub>2</sub> and R<sub>4</sub> and R<sub>5</sub> are H, C<sub>1</sub>-C<sub>4</sub> alkyl or R<sub>4</sub> and R<sub>5</sub> may combine to form a cyclic ring, R<sub>2</sub> and A may combine to form a cyclic ring; R<sub>3</sub> is carboxyl, its alkyl esters, carboxamide or substituted carboxamide, sulfonic acid, sulfonate esters, sulfonamide, substituted sulfonamide, phosphonic and phosphoric acids and their alkyl esters.

ATTY. DOCKET:UCIVN-035A  
Serial No. 10/810,497

2. (Withdrawn) A method according to No. 1 wherein the method is carried out to prevent or treat Hepatitis C.

3. (Presently Amended) A composition of matter having the formula:  
~~A method for inducing CD81 dependent antiproliferation in a human or veterinary patient, said method comprising the step of:~~  
~~(A) administering to the patient a therapeutically effective amount of an amantadine analogue having the formula:~~



wherein,


X is Boron or Carbon;

A is NH and NHR<sub>1</sub>, where R<sub>1</sub> is H, alkyl or imino-alkyl amino;


Z is a acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 10 carbon atoms, C=O, SO<sub>2</sub>, or absent; and R is an acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms or and -CH-R<sub>2</sub>R<sub>3</sub>, wherein R<sub>2</sub> is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, (CH<sub>2</sub>)<sub>n</sub>-Q, where n is 1-4 and Q is BSH, -OH, -NH<sub>2</sub>, -NH-CO-NH<sub>2</sub>, -NH-C=(NR<sub>4</sub>) NHR<sub>5</sub>, -COOH and its alkyl esters, and -CONH<sub>2</sub> and R<sub>4</sub> and R<sub>5</sub> are H, C<sub>1</sub>-4 alkyl or R<sub>4</sub> and R<sub>5</sub> may combine to form a cyclic ring, R<sub>2</sub> and A may combine to form a cyclic ring; R<sub>3</sub> is carboxyl, its alkyl esters, carboxamide or substituted carboxamide, sulfonic acid, sulfonate esters, sulfonamide, substituted sulfonamide, phosphonic and phosphoric acids and their alkyl esters.

ATTY. DOCKET:UCIVN-035A  
Serial No. 10/810,497

4. (New) A composition according to claim 3 having the formula:




5. (New) A composition according to claim 3 having the formula:




ATTY. DOCKET:UCIVN-035A  
Serial No. 10/810,497

6. (New) A composition according to claim 3 having the formula:




7. (New) A composition according to claim 3 having the formula:



ATTY. DOCKET:UCIVN-035A  
Serial No. 10/810,497

8. (New) A composition according to claim 3 having the formula:



9. (New) A composition according to claim 3 having the formula:

